1.72
1.72 (-7.81%)
As of Mar 06, 2024
Spero Therapeutics, Inc. [SPRO]
Source:
Company Overview
We are a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant, or MDR, bacterial infections and rare diseases. Our most advanced product candidate, Tebipenem Pivoxil Hydrobromide, or tebipenem HBr, is designed to be the first oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Treatment with effective orally administrable antibiotics may prevent hospitalizations for serious infections and enable earlier, more convenient and cost-effective treatment of patients after hospitalization.
Country | United States |
Headquarters | cambridge, massachusetts |
Phone Number | 857-242-1600 |
Industry | manufacturing |
CEO | Ankit Mahadevia, M.D. |
Website | www.sperotherapeutics.com |